Overview: Oncology Genetic Mapping TestIntroduction: The Oncology Genetic Mapping Test maps genetic mutations to guide cancer treatment, targeting tumors causing pain or weight loss. Following 2023 ASCO guidelines, it uses PCR for high specificity, aiding in cancer screening. This test is critical for guiding personalized treatment and improving outcomes in molecular pathology for cancer patients.
Other Names: Oncology Mapping Assay, Cancer Genomic Profiling Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Oncology genetic mapping began in the 2000s with cancer research. PCR-based assays emerged in the 2010s, improving accuracy for mutation detection.
Purpose: Guides cancer treatment by identifying genetic mutations in patients with tumors causing pain or weight loss.
Test Parameters: 1. Cancer-Related Mutations
Pretest Condition: No fasting required. Collect whole blood or tissue at any time. Report tumor symptoms and treatment history.
Specimen: 2-5 mL whole blood (EDTA) or 0.5-2 cma³ tissue (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document pain, weight loss, or cancer history. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for targeted therapy.
Procedural Considerations: Uses PCR to map cancer-related mutations. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low DNA yield or poor sample quality can affect results. Tumor heterogeneity may impact findings.
Clinical Significance: Identified mutations guide targeted therapies (e.g., EGFR inhibitors). Negative results may require alternative testing.
Specialist Consultation: Consult an oncologist for result interpretation.
Additional Supporting Tests: Biopsy, imaging, or liquid biopsy to confirm genomic findings.
Test Limitations: Tumor heterogeneity may miss mutations. Results require clinical correlation.
References: ASCO Cancer Guidelines, 2023; Journal of Clinical Oncology, Frampton GM, 2022.
